네이처셀
꿈틀 꿈틀 뇌졸증 - 일본 줄기세포 치료허가 준비중
올더웨이
조회1284
2020. 10. 28.
Athersys Preps MultiStem® Stroke Therapy for Approval Under Japan’s RegenMed Law
Athersys’s MultiStem® cell therapy is in Phase III clinical trials in the U.S., and with Japanese partner Healios K.K. in Japan, to treat ischemic stroke and acute respiratory distress syndrome (ARDS).
The therapy has the equivalent of Fast Track status in Japan. In the U.S., it is believed to be the only cell therapy treatment for ARDS that has both FastTrack and RMAT designations.
이번 주 좋은 소식 들려올려나?
- 이전글
- 트윗사진 건물!
- 다음글
- 일본 코로나 신청건에 대해서
전문가방송
1/3
연관검색종목 04.27 05:00 기준
0/1000 byte